Xin Liu

Summary

Affiliation: Pennsylvania State University
Country: USA

Publications

  1. ncbi Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia
    Xin Liu
    Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA
    Blood 116:4192-201. 2010
  2. ncbi The spectrum of large granular lymphocyte leukemia and Felty's syndrome
    Xin Liu
    Department of Medicine, Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA
    Curr Opin Hematol 18:254-9. 2011
  3. ncbi Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway
    Jun Yang
    Penn State Hershey Cancer Institute, Department of Medicine, College of Medicine, Pennsylvania State University, Hershey, PA, USA
    Blood 115:51-60. 2010
  4. ncbi Development and use of ceramide nanoliposomes in cancer
    Rebecca J Watters
    Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA
    Methods Enzymol 508:89-108. 2012
  5. ncbi Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
    Aijun Liao
    Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Blood 118:2793-800. 2011
  6. ncbi HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy
    Tong Ren
    Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Biol Chem 287:34683-93. 2012
  7. ncbi Network model of survival signaling in large granular lymphocyte leukemia
    Ranran Zhang
    Penn State Hershey Cancer Institute and Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Proc Natl Acad Sci U S A 105:16308-13. 2008
  8. ncbi Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets
    Francis LeBlanc
    Penn State Hershey Cancer Institute, Experimental Therapeutics, Room 4427, 500 University Drive, PO Box 850, Hershey, PA 17033 0850, USA
    Future Oncol 8:787-801. 2012
  9. ncbi Targeting sphingosine-1-phosphate receptors in cancer
    Rebecca J Watters
    Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, 17033, USA
    Anticancer Agents Med Chem 11:810-7. 2011
  10. ncbi Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation
    Kenichiro Doi
    Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Biol Chem 287:10224-35. 2012

Collaborators

  • Jun Yang
  • Mark Kester
  • Dan Zhang
  • Rongshi Li
  • Yan Liu
  • Fanxue Meng
  • Jong K Yun
  • Ravi Kothapalli
  • Thomas P Loughran
  • Rebecca J Watters
  • Hong Gang Wang
  • Mithun Vinod Shah
  • Ranran Zhang
  • Francis LeBlanc
  • Kenichiro Doi
  • Tong Ren
  • Shantu Amin
  • Shen Shu Sung
  • Alden Dewey
  • Aijun Liao
  • Colin Campbell
  • Reka Albert
  • Chunwei Cheng
  • Shao Cong Sun
  • Andy Awwad
  • Ernst Schonbrunn
  • Wanda Manieri
  • Said Sebti
  • Hua Cheng
  • Gowdahalli Krishnegowda
  • Melissa A Tran
  • Yong Qin
  • GARY DAUGHDRILL
  • Wen Dong
  • Yoshinori Takahashi
  • Di Xiang
  • Hongwei Wu
  • Yunsheng Yuan
  • Lucy Q Zhang
  • Todd D Schell
  • Cesar Aliaga
  • Rebecca Watters
  • Kathleen Broeg
  • Nancy Ruth Jarbadan
  • Dhimant Desai
  • Leah Hirsch
  • Juilee Thakar
  • Kelly Loughran
  • Todd Fox
  • Kendall Thomas Baab
  • Yongping Li
  • Lindsay Ryland
  • Andrew Rogers
  • Thomas Loughran
  • Jason Liao
  • Jeremy S Haley
  • Su Fern Tan
  • Rosalyn Irby
  • Norman H Lee
  • Bryan Frank
  • Susan B Nyland
  • Ty Arrington

Detail Information

Publications13

  1. ncbi Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia
    Xin Liu
    Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA, USA
    Blood 116:4192-201. 2010
    ..These data suggest that in vivo targeting of survivin through delivery of nanoliposomal C₆-ceramide may be a promising therapeutic approach for a fatal leukemia...
  2. ncbi The spectrum of large granular lymphocyte leukemia and Felty's syndrome
    Xin Liu
    Department of Medicine, Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033 0850, USA
    Curr Opin Hematol 18:254-9. 2011
    ..This review paper seeks to discuss the underlying pathogenesis and therapeutic algorithm of RA, neutropenia and splenomegaly in the spectrum of LGL leukemia and Felty's syndrome...
  3. ncbi Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway
    Jun Yang
    Penn State Hershey Cancer Institute, Department of Medicine, College of Medicine, Pennsylvania State University, Hershey, PA, USA
    Blood 115:51-60. 2010
    ..These results suggest that targeting of PDGF-BB, a pivotal regulator for the long-term survival of leukemic LGLs, may be an important therapeutic strategy...
  4. ncbi Development and use of ceramide nanoliposomes in cancer
    Rebecca J Watters
    Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, Pennsylvania, USA
    Methods Enzymol 508:89-108. 2012
    ..Pegylated nanoliposomes eliminate this issue and are able to enhance the intracellular delivery of ceramide to cancer cells...
  5. ncbi Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia
    Aijun Liao
    Penn State Hershey Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Blood 118:2793-800. 2011
    ..These data demonstrate that therapeutic benefit of FTY720 may result from both altered sphingolipid metabolism as well as enhanced degradation of a key component of survival signaling...
  6. ncbi HTLV-2 Tax immortalizes human CD4+ memory T lymphocytes by oncogenic activation and dysregulation of autophagy
    Tong Ren
    Penn State Hershey Cancer Institute, Penn State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Biol Chem 287:34683-93. 2012
    ..The present study demonstrated the oncogenic properties of Tax2 in human T cells and also implicated Tax2 in serving as a molecular tool to generate distinct T cell subtype lines...
  7. ncbi Network model of survival signaling in large granular lymphocyte leukemia
    Ranran Zhang
    Penn State Hershey Cancer Institute and Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA
    Proc Natl Acad Sci U S A 105:16308-13. 2008
    ..The model will be useful in identifying potential therapeutic targets for T-LGL leukemia and generating long-term competent CTL necessary for tumor and cancer vaccine development...
  8. ncbi Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets
    Francis LeBlanc
    Penn State Hershey Cancer Institute, Experimental Therapeutics, Room 4427, 500 University Drive, PO Box 850, Hershey, PA 17033 0850, USA
    Future Oncol 8:787-801. 2012
    ..The lack of a curative therapy for LGL leukemia means that new treatment options are needed. Insight into the various dysregulated signaling pathways in LGL leukemia may provide novel therapeutic treatment modalities...
  9. ncbi Targeting sphingosine-1-phosphate receptors in cancer
    Rebecca J Watters
    Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, 17033, USA
    Anticancer Agents Med Chem 11:810-7. 2011
    ..In particular, pharmacological agents targeting these S1PRs will be discussed and their potential will be examined...
  10. ncbi Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation
    Kenichiro Doi
    Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033, USA
    J Biol Chem 287:10224-35. 2012
    ..Taken together, these results suggest that maritoclax represents a new class of Mcl-1 inhibitors, which antagonizes Mcl-1 and overcomes ABT-737 resistance by targeting Mcl-1 for degradation...
  11. ncbi Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach
    Colin Campbell
    Department of Physics, The Pennsylvania State University University Park, PA, USA
    Front Physiol 2:32. 2011
    ..Moreover, the model highlights differences in apoptosis rates that contribute to compromised CD8+ T cell responses and tumor progression, knowledge of which is essential for development of cancer immunotherapy...
  12. ncbi T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias
    Rebecca J Watters
    Penn State Hershey Cancer Institute, Pennsylvania State College of Medicine, Hershey, PA 17033 0850, USA
    Leuk Lymphoma 52:2217-25. 2011
    ..In order to establish new therapeutics it is important to understand the current state of LGL leukemia both in the clinic and in basic research...
  13. ncbi Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes
    Mithun Vinod Shah
    Penn State Hershey Cancer Institute, Milton S Hershey Medical College, Hershey, PA, USA
    Blood 112:770-81. 2008
    ..Collectively, these results show a role for sphingolipid-mediated signaling as a mechanism for long-term survival of CTLs. Therapeutic targeting of this pathway, such as use of FTY720, may have efficacy in LGL leukemia...